Quick answer
Hormone therapy lowers testosterone or blocks its effect, because prostate cancer uses this hormone to grow.1 It is added to radiotherapy for intermediate and high risk, it is the basis of treatment for metastatic disease, combined with other drugs, and it is used in some cases of PSA rising again.2 It is not indicated before a prostatectomy.2 The most common side effects are hot flashes, lower sex drive, erection problems, fatigue and bone loss, and supervised exercise helps.1,3
How it works
Almost all of a man's testosterone is made in the testicles, and a small amount in the adrenal glands.1 Prostate cancer cells use this hormone to grow, so lowering testosterone or blocking its effect slows the tumor.1
The goal is to bring testosterone down to castration level. The European guideline uses a limit of 50 ng/dL and considers below 20 ng/dL a better target.2
Types of hormone therapy
| Type | How it is given | What to know |
|---|---|---|
| Removal of the testicles (orchiectomy) | Surgery1 | Testosterone falls by 90% to 95%, permanently1 |
| LHRH agonists (leuprolide, goserelin, triptorelin) | Injection or implant1 | At first, testosterone rises for a while. A receptor blocker may be used in the first weeks to prevent this1 |
| LHRH antagonists (degarelix, relugolix) | Degarelix by injection; relugolix as a pill1 | Testosterone does not rise at the start1 |
| Receptor blockers (bicalutamide, enzalutamide, apalutamide, darolutamide) | Pill1 | Stop testosterone from acting on the cells1 |
| Hormone production inhibitor (abiraterone) | Pill1 | Reduces the production of male hormones in other parts of the body1 |
Receptor blockers and abiraterone are usually combined with castration by injection or surgery, depending on the situation.2
When it is used
| Situation | What the European guideline says |
|---|---|
| Before a prostatectomy | Not indicated2 |
| Intermediate risk, with radiotherapy | 4 to 6 months. Not needed for favorable ISUP 2 treated with stereotactic radiotherapy2 |
| High risk, with radiotherapy | 2 to 3 years2 |
| Locally advanced disease, with radiotherapy | At least 2 years2 |
| PSA rising quickly after surgery or radiotherapy | Enzalutamide with castration in cases like those in the EMBARK trial2 |
| Metastatic disease | Castration combined with abiraterone, apalutamide, enzalutamide or darolutamide; castration alone is not offered to men fit for the combination2 |
In the EMBARK trial of 1,068 men whose PSA doubled in 9 months or less after treatment, 87.3% of those given enzalutamide with leuprolide were free of metastases at 5 years, compared with 71.4% of those given leuprolide alone.6
In metastatic disease, adding a second drug to castration improved survival. In LATITUDE, with abiraterone, the risk of death fell by 38%.11 In CHAARTED, docetaxel chemotherapy added 13.6 months to median survival.10 Today the European guideline uses docetaxel only together with castration and abiraterone or darolutamide.2
How long it lasts with radiotherapy, and the trials behind it, are covered in radiotherapy for prostate cancer.
Side effects
- Hot flashes: affect 44% to 80% of men, usually start around the third month and often last as long as treatment continues.3
- Sex life: lower sex drive and erection problems.1
- Bones: loss of bone density. In an American study of 50,613 men, among those who lived 5 years or more, 19.4% of those on hormone therapy had a fracture, compared with 12.6% of those not treated.7
- Body and metabolism: loss of muscle and strength, weight gain, changes in cholesterol and insulin resistance.1 The European guideline also lists diabetes and anemia.3
- Heart: in a meta-analysis of observational studies, LHRH agonists were associated with 38% more nonfatal cardiovascular disease.8 In randomized trials, there were more cardiovascular events, with no overall rise in deaths from this cause.3
- Other: fatigue, mood changes and breast growth.1
How to reduce the side effects
For men on hormone therapy, the European guideline advises:3
- 12 weeks of supervised aerobic and strength exercise
- A healthy weight and diet, stopping smoking and no more than 2 drinks of alcohol a day
- A yearly check of blood sugar and cholesterol
- Calcium and vitamin D in the recommended amounts
- A bone density scan when starting long-term hormone therapy, and bone medication when bone loss is significant or there is a risk of fracture
In a meta-analysis of randomized trials in men with prostate cancer, the higher-quality trials showed better quality of life and less fatigue with exercise.9
Treatment with breaks
In intermittent hormone therapy, the drug is given in cycles with breaks, to try to delay resistance and improve quality of life during the breaks.1
- PSA rising after radiotherapy: in a trial of 1,386 men, median survival was 8.8 years with breaks and 9.1 years with continuous treatment, a difference without statistical importance. Breaks brought possible gains in hot flashes, sex drive, erections and fatigue.4
- Metastatic disease: in a trial of 1,535 men, median survival was 5.1 years with breaks and 5.8 years with continuous treatment, and the result was inconclusive.5 The European guideline now considers that continuous combination treatment has replaced this strategy in metastatic disease.2
When the cancer stops responding
Over time, the cancer may progress again even with testosterone at castration level. This is called castration-resistant prostate cancer. The European guideline requires testosterone below 50 ng/dL plus a sign of progression: PSA rising in three consecutive tests, new lesions on imaging or clear clinical worsening.2 At this stage, other treatments are available.2
How I approach it
In my practice, I do not prescribe hormone therapy while a patient is waiting for surgery, because there is no indication for it. When surgery is recommended for intermediate or high risk, I advise operating as soon as possible. I also see men whose PSA has risen again after surgery or radiotherapy.
When to see a urologist
- If you have been advised to have hormone therapy and want to understand why and for how long
- If your PSA has risen again after surgery or radiotherapy
- If you are on hormone therapy and have hot flashes, fatigue or questions about your bones
- If you want a second opinion on your treatment
Frequently asked questions
What is hormone therapy for prostate cancer?+
It is treatment that lowers testosterone or blocks its effect, because prostate cancer cells use this hormone to grow. It is also called androgen deprivation therapy (ADT).1
Does hormone therapy cure prostate cancer?+
In metastatic disease, it can delay progression and may extend survival, and doctors cannot predict how long it will keep working.1 In localized cancer, it is added to radiotherapy.2
Do I need hormone therapy before a prostatectomy?+
No. The European guideline says hormone therapy before surgery is not indicated.2 In my practice, I do not prescribe hormone therapy while a patient is waiting for surgery.
What are the side effects of hormone therapy?+
The most common are hot flashes, lower sex drive, erection problems, fatigue, weight gain, muscle loss and bone loss, with a higher risk of fracture.1,3 Hot flashes affect 44% to 80% of men.3
How long does hormone therapy last?+
It depends on the reason. With radiotherapy, 4 to 6 months for intermediate risk and 2 to 3 years for high risk. In metastatic disease, treatment is continuous and combined with another drug.2
Can hormone therapy be given with breaks?+
In men with rising PSA after radiotherapy, treatment with breaks gave survival similar to continuous treatment.4 In metastatic disease, the result was inconclusive, and the European guideline now favors continuous combination treatment.2,5
What is castration-resistant prostate cancer?+
It is when the cancer progresses again even with testosterone at castration level, below 50 ng/dL. Progression shows as PSA rising in consecutive tests or new lesions on imaging.2
References
- National Cancer Institute. Hormone Therapy for Prostate Cancer. 2024. NCI
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. Treatment chapter. EAU
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. Quality of life chapter. EAU
- Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895-903. PubMed
- Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314-1325. PubMed
- Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023;389(16):1453-1465. PubMed
- Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164. PubMed
- Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386-396. PubMed
- Bourke L, Smith D, Steed L, et al. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;69(4):693-703. PubMed
- Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-746. PubMed
- Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-360. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation
